Collaboration created world’s largest browsable resource linking rare protein-coding genetic variants to human disease
On Jul. 8, 2021, access to the world’s largest browsable resource linking rare protein-coding genetic variants to human…
On Jul. 8, 2021, access to the world’s largest browsable resource linking rare protein-coding genetic variants to human…
On Jun. 30, 2021, Novavax announced the publication of results from the final analysis of a pivotal Phase…
On Jun. 30, 2021, SIGA Technologies announced that it had provided TPOXX (tecovirimat) to Liverpool University Hospitals NHS…
On May 27, 2021, Sanofi and GlaxoSmithKline started enrolment in their Phase 3 clinical study to assess the…
On May 21, 2021, Moderna announced that the Ministry of Food and Drug Safety of South Korea (MFDS)…
On May 21, 2021, Novavax announced that the full results from the Phase 3, randomized, observer-blinded, placebo-controlled trial…
On May 21, 2021, Novavax announced participation in a mix-and-match (vaccine interchangeability) COVID-19 vaccine booster trial that led…
On Mar. 22, 2021, Oxford University announced that a Phase III study of the Oxford-AstraZeneca coronavirus vaccine conducted…
On Mar. 11, 2021, Novavax announced final efficacy of 96.4% against mild, moderate and severe disease caused by…
On Feb. 22, 2021, Novavax announced it had completed enrollment of PREVENT-19, its pivotal Phase 3 study in…
On Feb. 8, 2021, Pfizer and BioNTech announced publication in Nature Medicine of data from in vitro studies…
On Feb. 4, 2021, Novavax announced the start of the rolling review process for authorization of NVX-CoV2373, its…
On Feb. 3, 2021, Novavax announced that the company had executed a binding Heads of Terms agreement with…
On Jan. 28, 2021, Novavax announced that NVX-CoV2373, its protein-based COVID-19 vaccine candidate, had met the primary endpoint,…
On Jan. 26, 2021, OraSure Technologies announced that Chronomics had selected the OMNIgene-ORAL (OME-505) saliva collection device as…
On Jan. 25, 2021, Moderna announced results from in vitro neutralization studies of sera from individuals vaccinated with…
On Jan. 14, 2021, Twist Bioscience announced that it had started shipping its new synthetic RNA reference controls,…
On Jan. 11, 2021, T2 Biosystems announced that its T2SARS-CoV-2 Panel – a molecular diagnostic test that detects…
On Jan. 8, 2021, the FDA alerted clinical laboratory staff and health care providers that it was monitoring…
On Jan. 8, 2021, the COVID-19 vaccine developed by Moderna has today been given regulatory approval for supply…
On Jan. 4, 2021, a research partnership between scientists at Scripps Research and UC San Diego found the…
On Dec. 21, 2020, the WHO reported that authorities of the United Kingdom of Great Britain and Northern…
On Nov. 29, 2020, Moderna announced a supply agreement with the United Kingdom (UK) government for an additional…
On Nov. 20, 2020, the ‘European Food Safety Authority reported that within the past month more than 300…
On Nov. 17, 2020, Moderna announced a supply agreement with the government of the United Kingdom (UK) to…
On Nov. 16, 2020, the UK Department for Health and Social Care Testing Innovation Fund announced £12.2M funding…
On Nov. 11, 2020, the Serum Institute of India (SII) and Indian Council of Medical Research (ICMR) announced…
On Oct. 27, 2020, Moderna announced that the Medicines and Healthcare products Regulatory Agency (MHRA) in the United…
On Oct. 27, 2020, Novavax announced updates on its Phase 3 clinical development program of NVX-CoV2373, its COVID-19…
On Sept. 24, 2020, Novavax announced that it had initiated its first Phase 3 study to evaluate the…